{
    "organizations": [],
    "uuid": "30beb9c01d8b740f39f646a404763be34380e1ff",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/04/24/globe-newswire-aclaris-therapeutics-to-announce-first-quarter-2018-financial-results-on-may-8-2018.html",
    "ord_in_thread": 0,
    "title": "Aclaris Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "WAYNE, Pa., Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, will report financial results for first quarter 2018 on Tuesday, May 8, 2018 after U.S. financial markets close.\nManagement will conduct a conference call at 5:00 PM ET that day to discuss the Company’s financial results and provide a general business update. A live webcast of the event can be accessed on the Events and Presentations page on the Investors section of the Aclaris website at http://www.aclaristx.com/events-and-webcasts . A replay of the webcast will be archived on the Aclaris website following the event.\nTo participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 7386579 prior to the start of the call.\nAbout Aclaris Therapeutics, Inc.\nAclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology. Aclaris’ focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.\nContact:\nAclaris Contact\nMichael Tung, M.D.\nSenior Vice President\nCorporate Strategy/Investor Relations\n484-329-2140\nmtung@aclaristx.com\nSource:Aclaris Therapeutics, Inc.",
    "published": "2018-04-25T00:05:00.000+03:00",
    "crawled": "2018-04-25T01:01:10.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "wayne",
        "aclaris",
        "therapeutic",
        "nasdaq",
        "acrs",
        "biopharmaceutical",
        "company",
        "committed",
        "identifying",
        "developing",
        "commercializing",
        "innovative",
        "therapy",
        "address",
        "significant",
        "unmet",
        "need",
        "aesthetic",
        "medical",
        "dermatology",
        "immunology",
        "report",
        "financial",
        "result",
        "first",
        "quarter",
        "tuesday",
        "may",
        "financial",
        "market",
        "close",
        "management",
        "conduct",
        "conference",
        "call",
        "pm",
        "et",
        "day",
        "discus",
        "company",
        "financial",
        "result",
        "provide",
        "general",
        "business",
        "update",
        "live",
        "webcast",
        "event",
        "accessed",
        "event",
        "presentation",
        "page",
        "investor",
        "section",
        "aclaris",
        "website",
        "http",
        "replay",
        "webcast",
        "archived",
        "aclaris",
        "website",
        "following",
        "event",
        "participate",
        "live",
        "call",
        "please",
        "dial",
        "domestic",
        "international",
        "reference",
        "conference",
        "id",
        "prior",
        "start",
        "call",
        "aclaris",
        "therapeutic",
        "aclaris",
        "therapeutic",
        "biopharmaceutical",
        "company",
        "committed",
        "identifying",
        "developing",
        "commercializing",
        "innovative",
        "therapy",
        "address",
        "significant",
        "unmet",
        "need",
        "dermatology",
        "aesthetic",
        "medical",
        "immunology",
        "aclaris",
        "focus",
        "market",
        "segment",
        "medication",
        "treatment",
        "gap",
        "exist",
        "resulted",
        "first",
        "treatment",
        "raised",
        "seborrheic",
        "keratoses",
        "several",
        "clinical",
        "program",
        "develop",
        "medication",
        "potential",
        "treatment",
        "common",
        "wart",
        "alopecia",
        "areata",
        "vitiligo",
        "additional",
        "information",
        "please",
        "visit",
        "follow",
        "aclaris",
        "linkedin",
        "contact",
        "aclaris",
        "contact",
        "michael",
        "tung",
        "senior",
        "vice",
        "president",
        "corporate",
        "relation",
        "mtung",
        "source",
        "aclaris",
        "therapeutic",
        "inc"
    ]
}